Federal judge tosses out antitrust lawsuit against Eli Lilly, Sanofi over diabetes drug discounts

05 Feb 2024

Patent Infringement

A federal judge in New York dismissed an antitrust lawsuit against drugmakers alleging that they conspired to boost profits by limiting discounts on insulin beginning in 2020. Mosaic Health and Central Virginia Health Services, both nonprofit healthcare providers, filed the lawsuit in 2021 in the US District Court for the Western District of New York. They alleged that Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca broke state and federal laws by “suddenly, and in coordination with one another,” agreeing to limit drug discounts through the federal 340B program, which allows safety-net hospitals and clinics to buy drugs like insulin at cheaper prices.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Eli Lilly & Co.

Sanofi SAMosaic Health System

[+6]

Indications

Diabetes Mellitus

Targets

Drugs

Insulin (glucose-responsive smart patch)(North Carolina State University/University of North Carolina)

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.